Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans

Osteoarthritis and Cartilage

Volumn 18, Issue SUPPL. 1, 2010, Pages

  Egea, J ^a,b   Garcia A G ^a,b,c   Verges, J ^d   Montell, E ^d   Lopez M G ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d BIOIBERICA SA   (Spain)

Author keywords

Antiapoptotic effects; Antiinflammatory; Chondroitin sulfate

Indexed keywords

ANTIOXIDANT; CASPASE 3; CHONDROITIN SULFATE; DISACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEOCHONDROITIN SULFATE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; NEUROPROTECTIVE AGENT;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NERVE CELL; NERVE DEGENERATION; NERVE FIBER GROWTH; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UVEITIS; ANIMAL; DRUG EFFECTS; NERVE CELL PLASTICITY; NEURODEGENERATIVE DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHONDROITIN SULFATE PROTEOGLYCANS; CHONDROITIN SULFATES; HUMANS; NEURODEGENERATIVE DISEASES; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS;

EID: 77953812309     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.01.016     Document Type: Article

References (40)

1. Hardingham T.E., Muir H. Biosynthesis of proteoglycans in cartilage slices. Fractionation by gel chromatography and equilibrium density-gradient centrifugation. Biochem J 1972, 126:791-803.
2. Bucsi L., Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998, 6(Suppl A):31-36.
3. Uebelhart D., Thonar E.J., Delmas P.D., Chantraine A., Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998, 6(Suppl A):39-46.
4. Jackson C.G., Plaas A.H., Sandy J.D., Hua C., Kim-Rolands S., Barnhill J.G., et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010, 18:297-302.
5. Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996, 23:1385-1391.
6. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
7. Verbruggen G., Goemaere S., Veys E.M. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002, 21:231-243.
8. Uebelhart D., Malaise M., Marcolongo R., de Vathaire F., Piperno M., Mailleux E., et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004, 12:269-276.
9. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
10. Lequesne M. Symptomatic slow-action anti-arthritic agents: a new therapeutic concept?. Rev Rhum Ed Fr 1994, 61:75-79.
11. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
12. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
13. Reichenbach S., Sterchi R., Scherer M., Trelle S., Burgi E., Burgi U., et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007, 146:580-590.
14. Monfort J., Martel-Pelletier J., Pelletier J.P. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr Med Res Opin 2008, 24:1303-1308.
15. McAlindon T.E., LaValley M.P., Felson D.T. Efficacy of glucosamine and chondroitin for treatment of osteoarthritis. JAMA 2000, 284:1241.
16. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522.
17. Hochberg M.C., Clegg D.O. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage 2008, 16(Suppl 3):S22-S24.
18. Townsend K.P., Pratico D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005, 19:1592-1601.
19. Galtrey C.M., Fawcett J.W. The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res Rev 2007, 54:1-18.
20. Moon L.D., Asher R.A., Rhodes K.E., Fawcett J.W. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat Neurosci 2001, 4:465-466.
21. Bradbury E.J., Moon L.D., Popat R.J., King V.R., Bennett G.S., Patel P.N., et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002, 416:636-640.
22. Grimpe B., Silver J. A novel DNA enzyme reduces glycosaminoglycan chains in the glial scar and allows microtransplanted dorsal root ganglia axons to regenerate beyond lesions in the spinal cord. J Neurosci 2004, 24:1393-1397.
23. Carulli D., Laabs T., Geller H.M., Fawcett J.W. Chondroitin sulfate proteoglycans in neural development and regeneration. Curr Opin Neurobiol 2005, 15:116-120.
24. Morawski M., Bruckner M.K., Riederer P., Bruckner G., Arendt T. Perineuronal nets potentially protect against oxidative stress. Exp Neurol 2004, 188:309-315.
25. Canas N., Valero T., Villarroya M., Montell E., Verges J., Garcia A.G., et al. Chondroitin sulfate protects SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1 via phosphatidylinositol 3-kinase/Akt. J Pharmacol Exp Ther 2007, 323:946-953.
26. Sivasankaran R., Pei J., Wang K.C., Zhang Y.P., Shields C.B., Xu X.M., et al. PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration. Nat Neurosci 2004, 7:261-268.
27. Sato Y., Nakanishi K., Tokita Y., Kakizawa H., Ida M., Maeda H., et al. A highly sulfated chondroitin sulfate preparation, CS-E, prevents excitatory amino acid-induced neuronal cell death. J Neurochem 2008, 104:1565-1576.
28. Huang H., Lung H.L., Leung K.N., Tsang D. Selective induction of tumor necrosis factor receptor type II gene expression by tumor necrosis factor-alpha in C6 glioma cells. Life Sci 1998, 62:889-896.
29. Nelson T.J., Alkon D.L. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 2005, 280:7377-7387.
30. Takeuchi H., Jin S., Wang J., Zhang G., Kawanokuchi J., Kuno R., et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 2006, 281:21362-21368.
31. Culbert A.A., Skaper S.D., Howlett D.R., Evans N.A., Facci L., Soden P.E., et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem 2006, 281:23658-23667.
32. Akama K.T., Van Eldik L.J. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem 2000, 275:7918-7924.
33. Bauer J., Strauss S., Volk B., Berger M. IL-6-mediated events in Alzheimer's disease pathology. Immunol Today 1991, 12:422.
34. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. Faseb J 2001, 15:43-58.
35. Sparkman N.L., Buchanan J.B., Heyen J.R., Chen J., Beverly J.L., Johnson R.W. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 2006, 26:10709-10716.
36. Rojo L.E., Fernandez J.A., Maccioni A.A., Jimenez J.M., Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008, 39:1-16.
37. Rolls A., Avidan H., Cahalon L., Schori H., Bakalash S., Litvak V., et al. A disaccharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. Eur J Neurosci 2004, 20:1973-1983.
38. Rolls A., Cahalon L., Bakalash S., Avidan H., Lider O., Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. Faseb J 2006, 20:547-549.
39. Crespo D., Asher R.A., Lin R., Rhodes K.E., Fawcett J.W. How does chondroitinase promote functional recovery in the damaged CNS?. Exp Neurol 2007, 206:159-171.
40. Rolls A., Shechter R., London A., Segev Y., Jacob-Hirsch J., Amariglio N., et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med 2008, 5:e171.